Obstetric Complication clinical trials at University of California Health

4 in progress, 2 open to eligible people

Showing trials for

  • Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

    open to eligible females ages 14 years and up

    This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.

    at UCSF

  • Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

    open to eligible females

    This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis, sepsis, pneumonia, pyelonephritis and breast infection.

    at UCSF

  • Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

    Sorry, in progress, not accepting new patients

    A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy.

    at UCSF

  • Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

    Sorry, not yet accepting patients

    This is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pressure (BP) of <140/90 mmHg or to no treatment for non-severe hypertension < 160/110 mmHg (usual care). The primary endpoint is an adverse pregnancy composite comprised of preeclampsia with end-organ damage, medically indicated preterm delivery <37 weeks 0 days gestation, fetal/neonatal/infant death, or placental abruption.

    at UCSF

Our lead scientists for Obstetric Complication research studies include .

Last updated: